Crossmark

Revisiting the Anti-Drug Antibody Assay Drug Tolerance of a Commercial Biological Product

Crossref DOI link: https://doi.org/10.1208/s12248-025-01186-8

Published Online: 2025-12-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zanghi, James https://orcid.org/0000-0002-7457-6411
Yu, Nancy https://orcid.org/0009-0009-1966-8231
Andrews, Benjamin T. https://orcid.org/0009-0000-7947-3537
Chan, Phyllis https://orcid.org/0000-0003-1509-1526
Usdin, Maxime https://orcid.org/0009-0008-9271-0267
Chiu, Cecilia https://orcid.org/0000-0001-8797-9984
Lin, WeiYu https://orcid.org/0000-0003-4363-7848
Lin, Alyse https://orcid.org/0000-0003-1730-3713
Song, Yuan https://orcid.org/0009-0004-5840-3133
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2025-12-23
More Information

Article History

Received: 25 July 2025

Accepted: 13 November 2025

First Online: 23 December 2025

Declarations

:

: All authors are current employees of Genentech, a wholly owned subsidiary of the Roche Group, and held or currently hold Roche stock and/or stock options during their employment.